CMS

Federal Court Punts Regarding Remedy Related to CMS’ Invalidated Rule Concerning Medicare Hospital Outpatient Payment Rates for 340B Drugs
Federal Court Punts Regarding Remedy Related to CMS’ Invalidated Rule Concerning Medicare Hospital Outpatient Payment Rates for 340B Drugs
FDA Law Blog
FDA
CMS
Medicare
340B
Flag link:
CMS reopens coverage determination on next-gen sequencing for cancer patients
CMS reopens coverage determination on next-gen sequencing for cancer patients
Medtech Dive
CMS
Medicare
next generation sequencing
cancer
Flag link:
How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
Motley Fool
Gilead Sciences
Novartis
CMS
Medicare
CAR-T
Flag link:
Medicare proposes raising CAR-T pay, but reimbursement solution years away
Medicare proposes raising CAR-T pay, but reimbursement solution years away
Biopharma Dive
CMS
CAR-T
Medicare
reimbursement
Flag link:
CMS demo could pave the path to eliminating Part D rebates
CMS demo could pave the path to eliminating Part D rebates
BioCentury
CMS
drug pricing
Medicare Part D
drug rebates
Flag link:
Electronic Health Records: A Promising New Way To Fight the Opioid Epidemic
Electronic Health Records: A Promising New Way To Fight the Opioid Epidemic
Forbes
opioids
opioid crisis
EHRs
EMRs
CMS
Flag link:
Drug spending could rise 6.1 percent annually by 2020, federal projections show
Drug spending could rise 6.1 percent annually by 2020, federal projections show
Stat
drug spending
CMS
Flag link:
Medicare would cover CAR-T cell therapies under new CMS proposal
Medicare would cover CAR-T cell therapies under new CMS proposal
Marketwatch
Medicare
CAR-T
cell therapy
CMS
Novartis
Kymriah
Gilead Sciences
Yescarta
Flag link:
Governor moves to boost California's drug price bargaining power
Governor moves to boost California's drug price bargaining power
BioCentury
drug pricing
CMS
Medicaid
California
Flag link:
CMS rule cuts reimbursement for new Part B drugs
CMS rule cuts reimbursement for new Part B drugs
BioCentury
Medicare Part B
CMS
reimbursement
physician-administered drugs
Flag link:
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
Fierce Pharma
CMS
UnitedHealthcare
Medicare
JNJ
Remicade
biosimilars
Pfizer
Merck
Flag link:
Medtech reporting would change under new opioid law
Medtech reporting would change under new opioid law
Mass Device
opioids
opioid crisis
Medicare
Medicaid
CMS
devices
Flag link:
Standardization Of Drug Compendia That Support Off-Label Use Reimbursement Of Cancer Drugs
Standardization Of Drug Compendia That Support Off-Label Use Reimbursement Of Cancer Drugs
Forbes
off-label
oncology
oncologists
cancer
CMS
Flag link:
Medicare Part D to allow indication-driven formularies
Medicare Part D to allow indication-driven formularies
BioCentury
Medicare
Medicare Part D
CMS
formulary
Flag link:
No, Massachusetts, you can't run a PBM-style Medicaid formulary, feds say
No, Massachusetts, you can't run a PBM-style Medicaid formulary, feds say
Fierce Pharma
drug pricing
Massachusetts
Medicaid
CMS
PBMs
Flag link:
Pharma, payers clash over CMS Part D drug rebate plan
Pharma, payers clash over CMS Part D drug rebate plan
HealthcareDive
payers
CMS
Medicare Part D
Medicare
drug rebates
Flag link:
Abbvie, Amgen Deal on Humira Biosimilars Likely to Cost CMS More Than $1B
Abbvie, Amgen Deal on Humira Biosimilars Likely to Cost CMS More Than $1B
RAPS.org
AbbVie
Amgen
Humira
biosimilars
Medicare
Medicaid
CMS
Flag link:
Why regional reimbursement strategies could be right for medtech
Why regional reimbursement strategies could be right for medtech
Medical Design and Outsourcing
devices
reimbursement
CMS
Flag link:
Health Spending Projections By CMS Could Influence AHCA Votes
Health Spending Projections By CMS Could Influence AHCA Votes
Forbes
healthcare reform
CMS
American Health Care Act
Flag link:
Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Seeking Alpha
Mylan Labs
EpiPens
CMS
rebates
Medicare
Medicaid
Flag link:

Pages